Literature DB >> 16478611

[The surgical treatment of hemorrhoids].

Mario de Miguel1, Fabiola Oteiza, Miguel Angel Ciga, Héctor Ortiz.   

Abstract

Surgery is the most effective treatment in patients with symptomatic grade III-IV hemorrhoids who have not responded to outpatient treatment, when there is associated abnormalities (anal fissure, anal fistula, skin tags) and in thrombosed hemorrhoids. Hemorrhoidectomy is currently the "gold standard" treatment. Randomized controlled trials comparing open with closed hemorrhoidectomy show no significant differences in pain scores. Stapled hemorrhoidectomy produces less postoperative pain than hemorrhoidectomy but is less effective in terms of symptom control. No treatment is superior to others in reducing postoperative pain except the use of drugs and anesthetic techniques. In patients with prolapsed internal hemorrhoids and thrombosed hemorrhoids, treatment may initially consist of an urgent hemorrhoidectomy with the same results as those obtained with elective surgery.

Entities:  

Mesh:

Year:  2005        PMID: 16478611     DOI: 10.1016/s0009-739x(05)74639-x

Source DB:  PubMed          Journal:  Cir Esp        ISSN: 0009-739X            Impact factor:   1.653


  2 in total

1.  Recombinant streptokinase vs hydrocortisone suppositories in acute hemorrhoids: A randomized controlled trial.

Authors:  Francisco Hernández-Bernal; Georgina Castellanos-Sierra; Carmen M Valenzuela-Silva; Karem M Catasús-Álvarez; Osmany Martínez-Serrano; Odalys C Lazo-Diago; Cimara H Bermúdez-Badell; José R Causa-García; Juan E Domínguez-Suárez
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

2.  Recombinant streptokinase vs phenylephrine-based suppositories in acute hemorrhoids, randomized, controlled trial (THERESA-3).

Authors:  Francisco Hernández-Bernal; Georgina Castellanos-Sierra; Carmen M Valenzuela-Silva; Karem M Catasús-Álvarez; Roselin Valle-Cabrera; Ana Aguilera-Barreto; Pedro A López-Saura
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.